InvestSMART

Cynata Therapeutics Limited (ASX: CYP) - Announcements

- Current share price for CYP : $0.011

ASX company news and announcements for Cynata Therapeutics Limited (CYP) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Cynata Therapeutics Limited (CYP) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Cynata Therapeutics Limited (CYP), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Cynata Therapeutics Limited (CYP)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$3 Application for quotation of securities - CYP 17 Apr 2023 9:21AM $0.200 $0.011 fallen by 94.50%
$3 Ethics Committee Approval for Proposed aGvHD Phase 2 Trial 12 Apr 2023 9:37AM $0.225 $0.011 fallen by 95.11%
$3 Capital Raising Presentation 6 Apr 2023 9:26AM $0.265 $0.011 fallen by 95.85%
$3 Proposed issue of securities - CYP 6 Apr 2023 9:24AM $0.265 $0.011 fallen by 95.85%
$3 Cynata completes $5.0m Placement and launches SPP 6 Apr 2023 9:24AM $0.265 $0.011 fallen by 95.85%
$3 Trading Halt 4 Apr 2023 9:20AM $0.265 $0.011 fallen by 95.85%
$3 Notification of cessation of securities - CYP 3 Apr 2023 5:46PM $0.265 $0.011 fallen by 95.85%
$3 Cynata Adds New Sites for DFU Clinical Trial 16 Mar 2023 1:25PM $0.290 $0.011 fallen by 96.21%
$3 Appendix 4D & Half-Year Financial Statements 28 Feb 2023 3:05PM $0.300 $0.011 fallen by 96.33%
$3 Notification of cessation of securities - CYP 6 Feb 2023 5:44PM $0.340 $0.011 fallen by 96.76%
$3 Quarterly Activity Report & Appendix 4C 31 Jan 2023 1:27PM $0.325 $0.011 fallen by 96.62%
$3 Cynata Receives IRB Approval for aGvHD Clinical Trial 30 Jan 2023 9:06AM $0.310 $0.011 fallen by 96.45%
$3 Notice of Acceptance for Cynata Australian Patent 9 Jan 2023 12:41PM $0.295 $0.011 fallen by 96.27%
$3 Notification of cessation of securities - CYP 5 Jan 2023 5:29PM $0.315 $0.011 fallen by 96.51%
$3 Cynata Receives $1.65m R&D Tax Incentive Refund 5 Dec 2022 8:56AM $0.350 $0.011 fallen by 96.86%
$3 Appendix 3Y - Janine Rolfe 23 Nov 2022 11:23AM $0.350 $0.011 fallen by 96.86%
$3 Notification regarding unquoted securities - CYP 23 Nov 2022 11:20AM $0.350 $0.011 fallen by 96.86%
$3 Results of AGM 22 Nov 2022 12:57PM $0.355 $0.011 fallen by 96.90%
$3 AGM Presentations 22 Nov 2022 8:52AM $0.330 $0.011 fallen by 96.67%
$3 Conference Data Demonstrating Consistency of Cynata MSCs 16 Nov 2022 9:03AM $0.325 $0.011 fallen by 96.62%
$3 Notice of Allowance for Cynata US Patent 11 Nov 2022 9:15AM $0.300 $0.011 fallen by 96.33%
$3 Notification of cessation of securities - CYP 7 Nov 2022 4:52PM $0.300 $0.011 fallen by 96.33%
$3 New Kidney Transplantation Clinical Trial for Cynata & LUMC 2 Nov 2022 9:10AM $0.300 $0.011 fallen by 96.33%
$3 Quarterly Activity Report & Appendix 4C 31 Oct 2022 4:31PM $0.315 $0.011 fallen by 96.51%
$3 Annual Report to Shareholders 21 Oct 2022 4:51PM $0.325 $0.011 fallen by 96.62%

201 - 225 of 702 results

Page 9 of 29

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.